Trial Profile

A study to evaluate how well single and multiple doses of O3R-5671-PRO are tolerated in healthy adult subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COL 5671 (Primary)
Indications Inflammatory bowel diseases; Psoriasis
Focus Adverse reactions; First in man
Sponsors Coultreon Biopharma

Most Recent Events

28 Apr 2026 According to a Coultreon Biopharma media release, Onco3R Therapeutics is now called Coultreon Biopharma.
09 Jan 2026 According to an Onco3R Therapeutics media release,the company announced that dosing in the final cohort of the first-in-human study of O3R-5671 has been initiated.
09 Jan 2026 According to an Onco3R Therapeutics media release, data from this trial will be presented at at the 21st congress of the European Crohns and Colitis Organization (ECCO), which will take place in Stokholm, Sweden from February 18-21.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com